<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6355868</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">30705340</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">6355868</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">37387</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1038/s41598-018-37387-9</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Statistical information for the recruited patients.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Statistical information for the recruited patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Value</th><th>Variables</th><th>Value</th></tr></thead><tbody><tr><td colspan="2">Age (years)</td><td colspan="2">WHO, histological type (%)</td></tr><tr><td>   Mean ± std</td><td>51.4 ± 14.5</td><td>   III, anaplastic astrocytomas</td><td>17 (25)</td></tr><tr><td>   Range</td><td>16–74</td><td>   III, anaplastic oligodendrogliomas</td><td>9 (13.2)</td></tr><tr><td>Males/females (%)</td><td>48/68(70.6)</td><td>   III, anaplastic ependymomas</td><td>1 (1.5)</td></tr><tr><td colspan="2">Hemisphere (%)</td><td>   IV, glioblastoma</td><td>41 (60.3)</td></tr><tr><td>   Left</td><td>50 (73.5)</td><td colspan="2">Tumor size (<italic>mm</italic><sup>3</sup>)</td></tr><tr><td>   Right</td><td>16 (23.5)</td><td>   Mean ± std</td><td>53.9 ± 40.1</td></tr><tr><td>   Bilateral</td><td>2 (3)</td><td>   Range</td><td>1.7 200</td></tr><tr><td colspan="2">Main location (%)</td><td>Preoperative epilepsy (%)</td><td>27/68(39.7)</td></tr><tr><td>   Occipital</td><td>4 (5.9)</td><td colspan="2">Overall survival time(%)</td></tr><tr><td>   Temporal</td><td>20 (29.4)</td><td>   ≤650 days</td><td>29 (42.6)</td></tr><tr><td>   Parietal</td><td>7 (10.3)</td><td>   ≥650 days (dead)</td><td>27 (39.7)</td></tr><tr><td>   Frontal</td><td>31 (45.6)</td><td>   ≥650 days (live)</td><td>12 (17.6)</td></tr><tr><td>   Insula</td><td>6 (8.8)</td><td/><td/></tr></tbody></table></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Statistical information for the recruited patients.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Value</th><th>Variables</th><th>Value</th></tr></thead><tbody><tr><td colspan="2">Age (years)</td><td colspan="2">WHO, histological type (%)</td></tr><tr><td>   Mean ± std</td><td>51.4 ± 14.5</td><td>   III, anaplastic astrocytomas</td><td>17 (25)</td></tr><tr><td>   Range</td><td>16–74</td><td>   III, anaplastic oligodendrogliomas</td><td>9 (13.2)</td></tr><tr><td>Males/females (%)</td><td>48/68(70.6)</td><td>   III, anaplastic ependymomas</td><td>1 (1.5)</td></tr><tr><td colspan="2">Hemisphere (%)</td><td>   IV, glioblastoma</td><td>41 (60.3)</td></tr><tr><td>   Left</td><td>50 (73.5)</td><td colspan="2">Tumor size (mm3)</td></tr><tr><td>   Right</td><td>16 (23.5)</td><td>   Mean ± std</td><td>53.9 ± 40.1</td></tr><tr><td>   Bilateral</td><td>2 (3)</td><td>   Range</td><td>1.7 200</td></tr><tr><td colspan="2">Main location (%)</td><td>Preoperative epilepsy (%)</td><td>27/68(39.7)</td></tr><tr><td>   Occipital</td><td>4 (5.9)</td><td colspan="2">Overall survival time(%)</td></tr><tr><td>   Temporal</td><td>20 (29.4)</td><td>   ≤650 days</td><td>29 (42.6)</td></tr><tr><td>   Parietal</td><td>7 (10.3)</td><td>   ≥650 days (dead)</td><td>27 (39.7)</td></tr><tr><td>   Frontal</td><td>31 (45.6)</td><td>   ≥650 days (live)</td><td>12 (17.6)</td></tr><tr><td>   Insula</td><td>6 (8.8)</td><td/><td/></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Performance evaluation of different features and selection/reduction methods with 3-fold and 10-fold cross validation, respectively. *Significantly improved (p &lt; 0.05) performance compared with “dtf” only method, as measured by McNemar’s test.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table 2</label><caption><p>Performance evaluation of different features and selection/reduction methods with 3-fold and 10-fold cross validation, respectively. *Significantly improved (<italic>p</italic> &lt; 0.05) performance compared with “dtf” only method, as measured by McNemar’s test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Method</th><th>ACC (%)</th><th>SEN (%)</th><th>SPE (%)</th><th>PPR (%)</th><th>NPR (%)</th><th>Cross Validation</th></tr></thead><tbody><tr><td>dtf</td><td>62.96</td><td>66.39</td><td>58.53</td><td>63.18</td><td>65.28</td><td rowspan="7">3-fold</td></tr><tr><td>fc7*</td><td>81.04</td><td>85.87</td><td>77.94</td><td>73.28</td><td>89.42</td></tr><tr><td>fc6-PCA*</td><td>80.78</td><td>84.88</td><td>77.04</td><td>76.03</td><td>85.37</td></tr><tr><td>fc6-SR</td><td>77.11</td><td>85.39</td><td>71.01</td><td>67.25</td><td>86.53</td></tr><tr><td>dtf + fc7*</td><td><bold>90.66</bold></td><td>96.77</td><td><bold>85.04</bold></td><td><bold>85.82</bold></td><td>96.31</td></tr><tr><td>dtf + fc6-PCA*</td><td><bold>90.27</bold></td><td><bold>96.48</bold></td><td>84.76</td><td><bold>84.98</bold></td><td>94.05</td></tr><tr><td>dtf + fc6-SR*</td><td>86.68</td><td>93.51</td><td>82.39</td><td>78.64</td><td><bold>95.43</bold></td></tr><tr><td>dtf</td><td>63.23</td><td>67.24</td><td>60.25</td><td>60.71</td><td>66.21</td><td rowspan="7">10-fold</td></tr><tr><td>fc7*</td><td>82.35</td><td>86.20</td><td>79.48</td><td>75.76</td><td>88.58</td></tr><tr><td>fc6-PCA*</td><td>80.88</td><td>85.27</td><td>76.92</td><td>74.52</td><td>86.26</td></tr><tr><td>fc6-SR</td><td>77.94</td><td>85.60</td><td>71.80</td><td>69.35</td><td>87.04</td></tr><tr><td>dtf + fc7*</td><td><bold>90.46</bold></td><td><bold>95.82</bold></td><td>85.78</td><td><bold>84.81</bold></td><td>95.59</td></tr><tr><td>dtf + fc6-PCA*</td><td><bold>90.17</bold></td><td>94.83</td><td><bold>85.90</bold></td><td>84.33</td><td><bold>95.71</bold></td></tr><tr><td>dtf + fc6-SR*</td><td>86.76</td><td>93.10</td><td>82.05</td><td>79.41</td><td>94.12</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Performance evaluation of different features and selection/reduction methods with 3-fold and 10-fold cross validation, respectively. *Significantly improved (p &lt; 0.05) performance compared with “dtf” only method, as measured by McNemar’s test.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Method</th><th>ACC (%)</th><th>SEN (%)</th><th>SPE (%)</th><th>PPR (%)</th><th>NPR (%)</th><th>Cross Validation</th></tr></thead><tbody><tr><td>dtf</td><td>62.96</td><td>66.39</td><td>58.53</td><td>63.18</td><td>65.28</td><td rowspan="7">3-fold</td></tr><tr><td>fc7*</td><td>81.04</td><td>85.87</td><td>77.94</td><td>73.28</td><td>89.42</td></tr><tr><td>fc6-PCA*</td><td>80.78</td><td>84.88</td><td>77.04</td><td>76.03</td><td>85.37</td></tr><tr><td>fc6-SR</td><td>77.11</td><td>85.39</td><td>71.01</td><td>67.25</td><td>86.53</td></tr><tr><td>dtf + fc7*</td><td>90.66</td><td>96.77</td><td>85.04</td><td>85.82</td><td>96.31</td></tr><tr><td>dtf + fc6-PCA*</td><td>90.27</td><td>96.48</td><td>84.76</td><td>84.98</td><td>94.05</td></tr><tr><td>dtf + fc6-SR*</td><td>86.68</td><td>93.51</td><td>82.39</td><td>78.64</td><td>95.43</td></tr><tr><td>dtf</td><td>63.23</td><td>67.24</td><td>60.25</td><td>60.71</td><td>66.21</td><td rowspan="7">10-fold</td></tr><tr><td>fc7*</td><td>82.35</td><td>86.20</td><td>79.48</td><td>75.76</td><td>88.58</td></tr><tr><td>fc6-PCA*</td><td>80.88</td><td>85.27</td><td>76.92</td><td>74.52</td><td>86.26</td></tr><tr><td>fc6-SR</td><td>77.94</td><td>85.60</td><td>71.80</td><td>69.35</td><td>87.04</td></tr><tr><td>dtf + fc7*</td><td>90.46</td><td>95.82</td><td>85.78</td><td>84.81</td><td>95.59</td></tr><tr><td>dtf + fc6-PCA*</td><td>90.17</td><td>94.83</td><td>85.90</td><td>84.33</td><td>95.71</td></tr><tr><td>dtf + fc6-SR*</td><td>86.76</td><td>93.10</td><td>82.05</td><td>79.41</td><td>94.12</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>Tab3</table-id><table-label>Table 3</table-label><table-caption>Statistical information for the newly recruited 25 patients (validation dataset).</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table 3</label><caption><p>Statistical information for the newly recruited 25 patients (validation dataset).</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Value</th><th>Variables</th><th>Value</th></tr></thead><tbody><tr><td colspan="2">Age (years)</td><td colspan="2">WHO, histological type (%)</td></tr><tr><td>   Mean ± std</td><td>50.2 ± 13.0</td><td>   III, anaplastic astrocytomas</td><td>6 (24)</td></tr><tr><td>   Range</td><td>23–68</td><td>   III, anaplastic oligodendrogliomas</td><td>3 (12)</td></tr><tr><td>Males/females (%)</td><td>16/9</td><td>   III, anaplastic ependymomas</td><td>1 (4)</td></tr><tr><td colspan="2">Hemisphere (%)</td><td>   IV, glioblastoma</td><td>15 (60)</td></tr><tr><td>   Left</td><td>16 (64)</td><td colspan="2">Tumor size (<italic>mm</italic><sup>3</sup>)</td></tr><tr><td>   Right</td><td>8 (32)</td><td>   Mean ± std</td><td>35.8 ± 32.3</td></tr><tr><td>   Bilateral</td><td>1 (4)</td><td>   Range</td><td>8.4 99.3</td></tr><tr><td colspan="2">Main location (%)</td><td>   Preoperative epilepsy(%)</td><td>27(39.7)</td></tr><tr><td>   Occipital</td><td>1 (4)</td><td colspan="2">Overall survival time(%)</td></tr><tr><td>   Temporal</td><td>6 (24)</td><td>   ≤ 650 days</td><td>9 (36)</td></tr><tr><td>   Parietal</td><td>2 (8)</td><td>   ≥ 650 days (dead)</td><td>3 (12)</td></tr><tr><td>   Frontal</td><td>14 (56)</td><td>   ≥ 650 days (live)</td><td>13 (52)</td></tr><tr><td>   Insula</td><td>2 (8)</td><td/><td/></tr></tbody></table></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Statistical information for the newly recruited 25 patients (validation dataset).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Value</th><th>Variables</th><th>Value</th></tr></thead><tbody><tr><td colspan="2">Age (years)</td><td colspan="2">WHO, histological type (%)</td></tr><tr><td>   Mean ± std</td><td>50.2 ± 13.0</td><td>   III, anaplastic astrocytomas</td><td>6 (24)</td></tr><tr><td>   Range</td><td>23–68</td><td>   III, anaplastic oligodendrogliomas</td><td>3 (12)</td></tr><tr><td>Males/females (%)</td><td>16/9</td><td>   III, anaplastic ependymomas</td><td>1 (4)</td></tr><tr><td colspan="2">Hemisphere (%)</td><td>   IV, glioblastoma</td><td>15 (60)</td></tr><tr><td>   Left</td><td>16 (64)</td><td colspan="2">Tumor size (mm3)</td></tr><tr><td>   Right</td><td>8 (32)</td><td>   Mean ± std</td><td>35.8 ± 32.3</td></tr><tr><td>   Bilateral</td><td>1 (4)</td><td>   Range</td><td>8.4 99.3</td></tr><tr><td colspan="2">Main location (%)</td><td>   Preoperative epilepsy(%)</td><td>27(39.7)</td></tr><tr><td>   Occipital</td><td>1 (4)</td><td colspan="2">Overall survival time(%)</td></tr><tr><td>   Temporal</td><td>6 (24)</td><td>   ≤ 650 days</td><td>9 (36)</td></tr><tr><td>   Parietal</td><td>2 (8)</td><td>   ≥ 650 days (dead)</td><td>3 (12)</td></tr><tr><td>   Frontal</td><td>14 (56)</td><td>   ≥ 650 days (live)</td><td>13 (52)</td></tr><tr><td>   Insula</td><td>2 (8)</td><td/><td/></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>Tab4</table-id><table-label>Table 4</table-label><table-caption>Performance comparison across different features for the newly collected 25 patients. *Significantly improved (p &lt; 0.05) performance compared with “dtf” only method, as measured by McNemar’s test.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table 4</label><caption><p>Performance comparison across different features for the newly collected 25 patients. *Significantly improved (<italic>p</italic> &lt; 0.05) performance compared with “dtf” only method, as measured by McNemar’s test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>ACC (%)</th><th>SEN (%)</th><th>SPE (%)</th><th>PPR (%)</th><th>NPR (%)</th></tr></thead><tbody><tr><td>dtf</td><td>68</td><td>66.67</td><td>68.75</td><td>54.55</td><td>78.57</td></tr><tr><td>fc7*</td><td>80</td><td>77.78</td><td>81.25</td><td>75</td><td>86.67</td></tr><tr><td>dtf + fc7*</td><td><bold>88</bold></td><td><bold>88.9</bold></td><td><bold>87.5</bold></td><td><bold>80</bold></td><td><bold>93.3</bold></td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Performance comparison across different features for the newly collected 25 patients. *Significantly improved (p &lt; 0.05) performance compared with “dtf” only method, as measured by McNemar’s test.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>ACC (%)</th><th>SEN (%)</th><th>SPE (%)</th><th>PPR (%)</th><th>NPR (%)</th></tr></thead><tbody><tr><td>dtf</td><td>68</td><td>66.67</td><td>68.75</td><td>54.55</td><td>78.57</td></tr><tr><td>fc7*</td><td>80</td><td>77.78</td><td>81.25</td><td>75</td><td>86.67</td></tr><tr><td>dtf + fc7*</td><td>88</td><td>88.9</td><td>87.5</td><td>80</td><td>93.3</td></tr></tbody></table></div></transformed-table></extracted-table></extracted-tables-set>